Coravas-ez-10/10 Tablets - Atorvastatin 10mg + Ezetimibe 10mg Tablets

CORAVAS-EZ 10/10 Tablets combine two complementary lipid-lowering agents — Atorvastatin and Ezetimibe — for superior control of cholesterol levels. This dual-action formulation targets cholesterol synthesis and absorption simultaneously, helping patients achieve optimal lipid balance and reducing cardiovascular risk more effectively than monotherapy. By acting on both endogenous (hepatic) and exogenous (intestinal) pathways of cholesterol regulation, CORAVAS-EZ delivers comprehensive lipid management and proven cardioprotective benefits.

Atorvastatin (10 mg)

Belongs to the HMG-CoA Reductase Inhibitor (Statin) class.
Inhibits the rate-limiting step in cholesterol biosynthesis, leading to reduced LDL-C, total cholesterol, and triglycerides, while modestly increasing HDL-C.
Improves endothelial function, stabilizes atherosclerotic plaques, and reduces inflammatory markers.
Demonstrated to significantly lower cardiovascular morbidity and mortality in high-risk patients.

Ezetimibe (10 mg)

A selective cholesterol absorption inhibitor that acts at the brush border of the small intestine.
Inhibits absorption of dietary and biliary cholesterol without affecting triglyceride or fat-soluble vitamin absorption.
Reduces intestinal cholesterol delivery to the liver, leading to further upregulation of hepatic LDL receptors and enhanced clearance of LDL-C from the blood.
Together, Atorvastatin and Ezetimibe provide additive and synergistic lipid-lowering effects, offering greater LDL-C reduction than either drug alone.

CORAVAS-EZ 10/10 Tablets are indicated for

Primary hypercholesterolemia (Familial or Non-Familial)
Mixed dyslipidemia (Type IIa or IIb)
Patients not adequately controlled with statin monotherapy
Adjunct to diet and lifestyle modification to reduce total cholesterol, LDL-C, Apo-B, and triglycerides, and to increase HDL-C levels.